Login to Your Account

Alexza Brings in $40M from Biovail Deal to Develop Inhaled Antipsychotic

By Catherine Hollingsworth

Thursday, February 11, 2010
Alexza Pharmaceuticals Inc. and Biovail Laboratories International SRL have agreed to develop and commercialize Alexza's inhaled antipsychotic AZ-004 (Staccato loxapine) in the U.S. and Canada in a deal worth $130 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription